2023-06-01 07:07:56 ET
- Can-Fite Biopharma press release ( NYSE: CANF ): Q1 GAAP EPS of $0.00.
- Revenue of $0.2M (flat Y/Y).
For further details see:
Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2M2023-06-01 07:07:56 ET
For further details see:
Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...